HBI Deals+Insights / Healthcare Reform

Al Noor rears its ugly head in Mediclinic results

Mediclinic saw underlying EBITDA fall by 2.2% in the financial year 2017, described as “humbling” by its CEO, as challenges in the Middle East made their mark on its full year results.

We would welcome your thoughts on this story. Email your views to Claude Risner or call 0207 183 3779.